Chemours
487 hedge funds and large institutions have $2.72B invested in Chemours in 2022 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 161 increasing their positions, 153 reducing their positions, and 68 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 153
0.17% less ownership
Funds ownership: 71.28% → 71.11% (-0.17%)
6% less funds holding
Funds holding: 517 → 487 (-30)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
23% less capital invested
Capital invested by funds: $3.55B → $2.72B (-$825M)
31% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 68
37% less call options, than puts
Call options by funds: $45M | Put options by funds: $71.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$31.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.7M |
| 3 |
Amundi
Paris,
France
|
+$29.1M |
| 4 |
JP Morgan Chase
New York
|
+$21.5M |
| 5 |
AWAM
Appian Way Asset Management
New York
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$86.9M |
| 2 |
SC
Sessa Capital
New York
|
-$72.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$28.2M |
| 4 |
GC
Greenlight Capital
New York
|
-$22.4M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$17.5M |
CC Hedge Fund Activity: Q3 2022 in Review
487 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Chemours (CC) for Q3 2022, worth a combined $2.72B — down 23% from $3.55B a quarter earlier.
Sellers outnumbered buyers: 68 funds closed out of CC and 47 opened new positions — a net loss of 21 holders — while 153 trimmed existing stakes and 161 added.
The largest buyer was Balyasny Asset Management, adding an estimated $31.2M. The largest seller was Fidelity Investments, cutting an estimated $86.9M.
- 487 institutional investors held Chemours (CC) as of Q3 2022, down from 517 in Q2 2022.
- Funds reported $2.72B of Chemours stock for Q3 2022, down 23% quarter-over-quarter.
- 47 funds opened new Chemours positions in Q3 2022 and 68 closed out, a net change of -21 holders.
- The largest Chemours buyer in Q3 2022 was Balyasny Asset Management, an estimated $31.2M added.
- The largest Chemours seller in Q3 2022 was Fidelity Investments, an estimated $86.9M sold.
Based on aggregated 13F filings for Q3 2022.